Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106156 | 1.00 | CSF1R (0.47) | CSF1RGBA1CYP1A1CYP1B1HPGDS | |
| SCHEMBL3407214 | 0.85 | PFKFB3 (0.42) | HPGDSPFKFB3 | |
| SCHEMBL3407332 | 0.84 | HPGDS (0.48) | HPGDSPFKFB3 | |
| SCHEMBL3403238 | 0.84 | HPGDS (0.48) | HPGDSPFKFB3 | |
| SCHEMBL1615470 | 0.81 | GBA1 (0.49) | GBA1JAK2JAK3MAPK1CYP3A4 | |
| SCHEMBL1615467 | 0.81 | GBA1 (0.49) | GBA1JAK2JAK3MAPK1CYP3A4 | |
| SCHEMBL3401134 | 0.75 | FADS1 (0.41) | JAK2JAK3PFKFB3 | |
| SCHEMBL3404459 | 0.73 | FADS1 (0.43) | GBA1PFKFB3 | |
| SCHEMBL3403995 | 0.73 | FADS1 (0.55) | MAPK1CYP3A4PFKFB3 | |
| SCHEMBL3401133 | 0.73 | FADS1 (0.43) | GBA1JAK2JAK3PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | claimed |
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2252372-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | CSF1R 1647/4885GBA1 1562/4885CYP1A1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.